Quick Answer
ENANTA PHARMACEUTICALS INC reported Research And Development Expense of $106.74 million for the year ending 2025.
- ENANTA PHARMACEUTICALS INC showed a decrease of -18.8% in Research And Development Expense from 2024 to 2025.
- This data is from ENANTA PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on November 19, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2012: $4.93 million | Q4 2012: $4.80 million | Q1 2013: $3.70 million | Q2 2013: $4.04 million | Q4 2013: $4.26 million | Q1 2014: $4.72 million | Q2 2014: $4.55 million | Q4 2014: $4.52 million | Q1 2015: $5.37 million | Q2 2015: $6.25 million | Q4 2015: $9.03 million | Q1 2016: $9.14 million | Q2 2016: $10.79 million | Q4 2016: $12.53 million | Q1 2017: $13.00 million | Q2 2017: $15.41 million | Q4 2017: $17.96 million | Q1 2018: $21.48 million | Q2 2018: $28.49 million | Q4 2018: $34.88 million | Q1 2019: $34.16 million | Q2 2019: $34.46 million | Q4 2019: $32.78 million | Q1 2020: $32.61 million | Q2 2020: $34.68 million | Q4 2020: $36.67 million | Q1 2021: $41.51 million | Q2 2021: $46.99 million | Q4 2021: $48.55 million | Q1 2022: $42.09 million | Q2 2022: $39.09 million | Q4 2022: $40.90 million | Q1 2023: $43.47 million | Q2 2023: $42.99 million | Q4 2023: $36.37 million | Q1 2024: $35.59 million | Q2 2024: $28.74 million | Q4 2024: $27.66 million | Q1 2025: $28.07 million | Q2 2025: $27.21 million | Q4 2025: $20.86 million.
- Over the full 15 years of available data (2011 to 2025), ENANTA PHARMACEUTICALS INC's Research And Development Expense has grown by 824.4%.
- Historical annual values: Fiscal year 2025: $106.74 million | Fiscal year 2024: $131.48 million | Fiscal year 2023: $163.52 million | Fiscal year 2022: $164.52 million | Fiscal year 2021: $174.11 million | Fiscal year 2020: $136.76 million | Fiscal year 2019: $142.21 million | Fiscal year 2018: $94.86 million | Fiscal year 2017: $57.45 million | Fiscal year 2016: $40.46 million | Fiscal year 2015: $23.19 million | Fiscal year 2014: $18.74 million | Fiscal year 2013: $16.84 million | Fiscal year 2012: $15.12 million | Fiscal year 2011: $11.55 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: